Quick Answer
BioCardia, Inc. reported R&D Expense of $4.96 million for fiscal year 2025.
BioCardia, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.96M | +13.1% |
| 2024 | $4.39M | -43.2% |
| 2023 | $7.73M | -12.5% |
| 2022 | $8.83M | +3.2% |
| 2021 | $8.56M | -12.8% |
| 2020 | $9.81M | +14.6% |
| 2019 | $8.56M | +1.3% |
| 2018 | $8.45M | +45.8% |
| 2017 | $5.80M | +74.1% |
| 2016 | $3.33M | +119.4% |
| 2015 | $1.52M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $936.0K | +0.5% | -31.6% |
| June 30, 2025 | $1.37M | +71.0% | -10.6% |
| March 31, 2025 | $1.53M | +23.3% | +64.3% |
| September 30, 2024 | $931.0K | -50.3% | +16.4% |
| June 30, 2024 | $800.0K | -65.4% | -35.5% |
| March 31, 2024 | $1.24M | -47.9% | -33.7% |
| September 30, 2023 | $1.87M | -12.7% | -19.1% |
| June 30, 2023 | $2.31M | +0.4% | -2.9% |
- BioCardia, Inc. showed an increase of +13.1% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, BioCardia, Inc.’s r&d expense has grown by 226.9% (from $1.52 million to $4.96 million).
- The most recent figure is from BioCardia, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: